First Business Financial Services Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 13.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,042 shares of the company’s stock after purchasing an additional 608 shares during the period. First Business Financial Services Inc.’s holdings in Eli Lilly and were worth $942,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also modified their holdings of the business. Perennial Advisors LLC bought a new position in shares of Eli Lilly and in the 4th quarter valued at about $31,000. Retirement Group LLC acquired a new stake in Eli Lilly and in the 4th quarter valued at about $33,000. DB Wealth Management Group LLC acquired a new stake in Eli Lilly and in the 4th quarter valued at about $34,000. Accel Wealth Management acquired a new stake in Eli Lilly and in the 4th quarter valued at about $37,000. Finally, Archer Investment Corp lifted its stake in Eli Lilly and by 83.3% in the 4th quarter. Archer Investment Corp now owns 220 shares of the company’s stock valued at $37,000 after purchasing an additional 100 shares during the last quarter. 75.59% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on LLY shares. Morgan Stanley raised their target price on shares of Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a research note on Thursday, February 4th. Mizuho raised their price objective on shares of Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday, February 1st. Bank of America raised their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, January 22nd. Truist raised their price objective on shares of Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Finally, Truist Securities raised their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $196.27.
Shares of NYSE:LLY opened at $187.05 on Friday. The company’s 50 day simple moving average is $190.43 and its 200 day simple moving average is $174.21. The stock has a market capitalization of $179.38 billion, a price-to-earnings ratio of 30.56, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. Eli Lilly and Company has a 1 year low of $129.21 and a 1 year high of $218.00.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Thursday, January 28th. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.35 by $0.40. The business had revenue of $7.44 billion for the quarter, compared to analysts’ expectations of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same period last year, the firm posted $1.73 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 7.56 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 125,284 shares of the business’s stock in a transaction on Monday, March 8th. The shares were sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the sale, the insider now owns 110,422,933 shares of the company’s stock, valued at $23,154,584,820.77. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: Stock Portfolio Tracker
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.